SPRB
SPRB clinical trials: SPRUCE BIOSCIENCES, INC.
Every trial on ClinicalTrials.gov where SPRUCE BIOSCIENCES, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 8
- Trials linked
- 8
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
SPRB on the catalyst calendar · SPRB registry changes
- Primary completion Not registeredNo phase registeredNCT07733856Early Access Treatment With Tralesinidase Alfa in Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B)Spruce Biosciences · Mucopolysaccharidosis Type IIIBAvailableSPRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2033Sponsor estimatePhase 3NCT07579910Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B)Spruce Biosciences · MPS IIIBNot yet recruitingSPRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2025ActualPhase 2NCT05128942A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAHSpruce Biosciences · Congenital Adrenal HyperplasiaTerminatedSPRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2, 2019ActualPhase 2NCT03257462Study of SPR001 in Adults With Classic Congenital Adrenal HyperplasiaSpruce Biosciences · Congenital Adrenal HyperplasiaCompletedSPRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 3, 2023ActualPhase 2NCT05370521A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal AndrogensSpruce Biosciences · Polycystic Ovary SyndromeTerminatedSPRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 31, 2024ActualPhase 2NCT04544410A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAHSpruce Biosciences · Congenital Adrenal HyperplasiaTerminatedSPRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 9, 2024ActualPhase 2NCT04457336A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAHSpruce Biosciences · Congenital Adrenal HyperplasiaTerminatedSPRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 8, 2019ActualPhase 2NCT03687242Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal HyperplasiaSpruce Biosciences · Congenital Adrenal HyperplasiaCompletedSPRBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 8 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner